Announcement on Progress in Technology Transfer (Entrustment) Contract Signed by a Wholly-owned Subsidiary and Entry of Daprodustat Tablets into Phase III Clinical Trial (Confirmatory Clinical Study)

About this update from Harbin Pharmaceutical Group Co., Ltd. Class A

Announcement on Progress in Technology Transfer (Entrustment) Contract Signed by a Wholly-owned Subsidiary and Entry of Daprodustat Tablets into Phase III Clinical Trial (Confirmatory Clinical Study) The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Harbin Pharmaceutical Group Co., Ltd. Class A